Prevención de Enfermedad Hemolítica Perinatal severa con Inmunoglobulina Intravenosa en paciente altamente sensibilizada

  • Villalobos Andueza C
  • Monckeberg Balmaceda M
  • Kottman González C
  • et al.
N/ACitations
Citations of this article
18Readers
Mendeley users who have this article in their library.

Abstract

Perinatal Hemolytic Disease is uncommon today due to its prevention. However, there are cases of highly sensitized mothers who wish to have a child, that forces this desired pregnancy to be controlled in a special way and be subjected to invasive procedures not exempt from fetal morbidity and mortality. Prenatal use of human inmunoglobulin in the mother may represent a therapeutic alternative. We present a case in which its use prevented the development of intrauterine disease and favored a good neonatal evolution despite the fact that the initial prognosis was very adverse.

Cite

CITATION STYLE

APA

Villalobos Andueza, C., Monckeberg Balmaceda, M. J., Kottman González, C., Arteaga Rocuant, J. C., & Oyarzún Ebensperger, E. (2021). Prevención de Enfermedad Hemolítica Perinatal severa con Inmunoglobulina Intravenosa en paciente altamente sensibilizada. Revista Chilena de Obstetricia y Ginecología, 86(1), 76–80. https://doi.org/10.4067/s0717-75262021000100076

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free